CFTR and cystic fibrosis: HDR correction of CFTR F508del achieved gene editing rates similar to our PE approach and led to the finding that such levels of F508del correction would be clinically beneficial if replicated in vivo, as supported by several in vitro studies79–81 and clinical analyses of milder CF genotypes82–85.